8-K: BioSig Technologies' Near Field Tracking Algorithm Surpasses 100 Patient Cases, Demonstrating Clinical Adoption and Efficiency Gains

BioSig Technologies announces that its Near Field Tracking algorithm has been used in over 100 patient cases, showcasing its clinical adoption and ability to reduce ablation time.

Summary

• BioSig Technologies has announced that its Near Field Tracking (NFT) algorithm, a feature of the PURE EP Platform, has been used in over 100 patient cases.
• The NFT algorithm, launched in Q4 2023, provides real-time, color-coded feedback on tissue characteristics to electrophysiologists.
• The company reports that the algorithm has been adopted by major medical centers and health systems.
• Clinical data suggests the NFT algorithm can reduce ablation time by approximately 66%.
• The PURE EP Platform is designed to provide clear cardiac signal data, improving the accuracy of cardiac arrhythmia procedures.
• A blinded clinical study showed that electrophysiologists rated PURE EP as superior to conventional systems for 75.2% of signal samples.
• The global electrophysiology (EP) market is projected to reach $16 billion in 2028, with an 11.2% growth rate.

Sentiment

Score: 8

Explanation: The document presents positive clinical results and market growth potential, indicating a strong positive sentiment. The successful implementation of the NFT algorithm and its impact on procedure times are encouraging.

Positives

• The Near Field Tracking algorithm has achieved significant clinical adoption, with over 100 cases completed.
• The algorithm has demonstrated a substantial reduction in ablation time, approximately 66%.
• The PURE EP Platform has been rated superior to conventional systems in a clinical study.
• The platform is being used at well-respected healthcare systems, including Mayo Clinic and Cleveland Clinic.
• The company is exploring expanded applications for the NFT algorithm.

Risks

• The company faces risks associated with maintaining its Nasdaq listing.
• There are risks related to the company's cost reduction plan and its ability to achieve targeted cash burn reduction.
• The company is subject to risks associated with pandemics or worldwide health issues.
• There are risks related to manufacturing its products on a commercial scale.
• The company faces risks related to securing regulatory approval for its products.
• The company is subject to risks related to competition and the loss of key personnel.

Future Outlook

The company is investigating expanded applications for the Near Field Tracking algorithm in collaboration with early adopters.

Management Comments

• BioSigs PURE EP Platform and its new algorithms are pioneering the way in the automatic interpretation of cardiac cellular reaction to catheter energy delivered, commented Hicham El Masry, MD, FHRS, Cardiac Electrophysiologist at Mayo Clinic Arizona.
• NFT is a unique algorithm for assessing lesion efficiency and increases my procedural efficiency and confidence when it comes to distinguishing between healthy and scar or ablated tissue, stated Hicham El Masry, MD, FHRS.
• We are excited about the unique value we are providing our physicians, and proud to have achieved the milestone of 100 NFT cases in less than 90 days, added Zachary Koch, Principal Advisor of Product Development at BioSig.
• As the lead researcher at BioSig in the design and capabilities of NFT, I am encouraged by the algorithms impact on case time, safety, and efficacy, stated Zachary Koch.

Industry Context

This announcement highlights the growing adoption of advanced technologies in the electrophysiology market, where there is a focus on improving procedure efficiency and accuracy. The company's technology is positioned to address the increasing demand for better cardiac signal visualization and treatment options.

Comparison to Industry Standards

• The reported 66% reduction in ablation time with BioSig's NFT algorithm is a significant improvement compared to traditional methods, which often require longer procedure times.
• The PURE EP Platform's 75.2% superiority rating in signal quality compared to conventional systems suggests a potential competitive advantage over established players in the cardiac signal processing market.
• The global EP market is projected to reach $16B in 2028, indicating a large and growing market opportunity for BioSig's technology.
• Competitors in the EP market include companies like Abbott, Boston Scientific, and Medtronic, which also offer cardiac mapping and ablation technologies. BioSig's focus on signal clarity and real-time feedback positions it as a potential disruptor in this space.

Stakeholder Impact

• Shareholders may view the positive clinical results and market growth potential favorably.
• Physicians will benefit from the improved efficiency and accuracy of the PURE EP Platform.
• Patients may experience shorter procedure times and improved outcomes.
• The company's employees may be positively impacted by the company's growth and success.

Next Steps

• The company is investigating expanded applications for the NFT algorithm.
• The company will continue to support the adoption of the PURE EP Platform at leading medical centers.

Key Dates

Keywords

Near Field Tracking, PURE EP Platform, cardiac ablation, electrophysiology, arrhythmia, medical technology, signal processing, ablation time, clinical adoption